Dermatology
Page 1 • 2 itemsAccess global dermatology market intelligence, drug development trends, and regulatory insights for pharma BD, investors, and analysts.
CLINUVEL Receives EMA Approval for SCENESSE Phase III Vitiligo Trial Starting 2026
CLINUVEL gets final EMA scientific advice for pivotal Phase III vitiligo study comparing SCENESSE with NB-UVB therapy, set to begin second half 2026.
Polycythemia Vera Market Transformation: 9 Companies Including Protagonist Therapeutics with Rusfertide to Enter by 2036
Nine pharmaceutical companies are advancing polycythemia vera treatments through clinical trials, with Protagonist Therapeutics' rusfertide leading market expansion by 2036.